Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600535 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer
A Phase 1 study, sponsored by Cougar Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00600535: Completed Phase 1 study, sponsored by Cougar Biotechnology.
NCT00600535 is a Phase 1 study that has completed, run by Cougar Biotechnology. The registered enrollment target is 31 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00600535, a Phase 1 study, has completed, sponsored by Cougar Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of capsule and tablet formulations of CB7630 (abiraterone acetate) taken with and without food in patients with prostate cancer.
Interventions
- DRUG Stage 1 Group 1: abiraterone acetate
- DRUG Stage 1 Group 2: abiraterone acetate
- DRUG Stage 2: abiraterone acetate
- DRUG Stage 3: abiraterone acetate
- DRUG Stage 3: glucocorticoid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-07 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
What the finished NCT00600535 record still lists
NCT00600535 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 5 interventions - of which Stage 1 Group 1: abiraterone acetate is the first listed.
NCT00600535 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00600535 about?
NCT00600535 is a clinical study titled "A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer". The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of capsule and tablet formulations of CB7630 (abiraterone acetate) taken with and without food in patients with prostate cancer.
What is the current status of trial NCT00600535?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2007-07. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00600535?
The interventions under investigation include: Stage 1 Group 1: abiraterone acetate (DRUG), Stage 1 Group 2: abiraterone acetate (DRUG), Stage 2: abiraterone acetate (DRUG), Stage 3: abiraterone acetate (DRUG), Stage 3: glucocorticoid (DRUG).
Who is sponsoring clinical trial NCT00600535?
This trial is sponsored by Cougar Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00600535's enrollment target sits among peer trials
31 1322nd of 2000 higher than 669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia